Floatz logo

mdg1021

Malignant Lymphoma

Medigene AGCell therapyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

289 Active assets in the Malignant Lymphoma cohort.

Asset / SponsorPhaseRating
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
The Lymphoma Academic Research Organisation
Phase 4BBB
VINBLASTINE
Intensity Therapeutics, Inc.
Phase 4BBB
VINCRISTINE SULFATE
Inhye Ahn
Phase 3BB
BLEOMYCIN
Shandong Provincial Hospital
Phase 4BB
PREDNISONE TABLETS
Beth Israel Deaconess Medical Center
Phase 4BB

View all 50 →

Same molecule, other indications

mdg1021 is also rated in:

acute lymphoblastic leukemiaDormant
CC
Indicative ·
43 / 100
View asset →
myeloproliferative neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
chronic myeloid leukemiaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →